Colgate’s Third-Century Plan positions it uniquely between research giants and liberal arts peers, by using strategic investments in research and signature programs ...
Seasoned Life Sciences Executive Joins to Lead Operations and Scale Lahjavida’s Dye-Drug Conjugate Platform COLORADO ...
Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the power of ...
Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative ...
Appointment strengthens Artis platform strategy in nucleic acid medicines in connection with pending Syngoi acquisitionSAN DIEGO--(BUSINESS WIRE)--Artis BioSolutions today announced the appointment of ...
BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568). The collaboration will integrate ...
RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.
The world’s first AI-based optical diagnostic platform offers potential for near-instant diagnosis of CSF rhinorrhea.
Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to ...
DES MOINES, IA, UNITED STATES, February 16, 2026 / EINPresswire.com / — Kelpak, the flagship liquid seaweed concentrate, was established in 1978 with a simple idea that still guides the company today.
BostonGene and Daiichi Sankyo are collaborating to integrate AI-driven translational intelligence into an antibody-drug ...
Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results